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Screening for fetal growth restriction with universal third 
trimester ultrasonography in nulliparous women in the 
Pregnancy Outcome Prediction (POP) study: a prospective 
cohort study
Ulla Sovio, Ian R White, Alison Dacey, Dharmintra Pasupathy, Gordon C S Smith
Summary
Background Fetal growth restriction is a major determinant of adverse perinatal outcome. Screening procedures 
for fetal growth restriction need to identify small babies and then diﬀ erentiate between those that are healthy and 
those that are pathologically small. We sought to determine the diagnostic eﬀ ectiveness of universal ultrasonic 
fetal biometry in the third trimester as a screening test for small-for-gestational-age (SGA) infants, and whether 
the risk of morbidity associated with being small diﬀ ered in the presence or absence of ultrasonic markers of fetal 
growth restriction.
Methods The Pregnancy Outcome Prediction (POP) study was a prospective cohort study of nulliparous women with 
a viable singleton pregnancy at the time of the dating ultrasound scan. Women participating had clinically indicated 
ultrasonography in the third trimester as per routine clinical care and these results were reported as usual (selective 
ultrasonography). Additionally, all participants had research ultrasonography, including fetal biometry at 28 and 
36 weeks’ gestational age. These results were not made available to participants or treating clinicians (universal 
ultrasonography). We regarded SGA as a birthweight of less than the 10th percentile for gestational age and screen 
positive for SGA an ultrasonographic estimated fetal weight of less than the 10th percentile for gestational age. 
Markers of fetal growth restriction included biometric ratios, utero-placental Doppler, and fetal growth velocity. We 
assessed outcomes for consenting participants who attended research scans and had a livebirth at the Rosie Hospital 
(Cambridge, UK) after the 28 weeks’ research scan.
Findings Between Jan 14, 2008, and July 31, 2012, 4512 women provided written informed consent of whom 
3977 (88%) were eligible for analysis. Sensitivity for detection of SGA infants was 20% (95% CI 15–24; 69 of 
352 fetuses) for selective ultrasonography and 57% (51–62; 199 of 352 fetuses) for universal ultrasonography (relative 
sensitivity 2·9, 95% CI 2·4–3·5, p<0·0001). Of the 3977 fetuses, 562 (14·1%) were identiﬁ ed by universal 
ultrasonography with an estimated fetal weight of less than the 10th percentile and were at an increased risk of 
neonatal morbidity (relative risk [RR] 1·60, 95% CI 1·22–2·09, p=0·0012). However, estimated fetal weight of less 
than the 10th percentile was only associated with the risk of neonatal morbidity (pinteraction=0·005) if the fetal abdominal 
circumference growth velocity was in the lowest decile (RR 3·9, 95% CI 1·9–8·1, p=0·0001). 172 (4%) of 
3977 pregnancies had both an estimated fetal weight of less than the 10th percentile and abdominal circumference 
growth velocity in the lowest decile, and had a relative risk of delivering an SGA infant with neonatal morbidity of 
17·6 (9·2–34·0, p<0·0001).
Interpretation Screening of nulliparous women with universal third trimester fetal biometry roughly tripled detection 
of SGA infants. Combined analysis of fetal biometry and fetal growth velocity identiﬁ ed a subset of SGA fetuses that 
were at increased risk of neonatal morbidity.
Funding National Institute for Health Research, Medical Research Council, Sands, and GE Healthcare.
Copyright © Sovio et al. Open Access article distributed under the terms of CC BY.
Introduction
Use of ultrasonography to identify small-for-gestational-
age (SGA) infants is widespread in contemporary 
obstetric practice.1,2 In the USA, UK, and many other 
countries women are not routinely scanned in late 
pregnancy, but are selected for third trimester 
ultrasonography on the basis of pre-pregnancy risk 
factors, development of obstetric complications, and 
serial measurement of symphyseal-fundal height.2,3 This 
approach identiﬁ es a third of SGA infants or fewer,4–6 and 
unidentiﬁ ed SGA is a common ﬁ nding in perinatal 
deaths.7,8 However, a meta-analysis9 of nine trials 
assessing universal late pregnancy ultrasonography, 
including about 27 000 women, showed no beneﬁ cial 
eﬀ ect, which led to the recommendation that it should 
not be oﬀ ered routinely in the third trimester.2,3
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Assessment of a screening programme could yield a 
negative result for three major reasons. First, the 
screening test could perform poorly—ie, have poor 
diagnostic eﬀ ectiveness. Second, screening might not be 
coupled with use of an eﬀ ective intervention—ie, the 
screening programme would not be clinically eﬀ ective. 
Third, both the screening test and intervention could be 
eﬀ ective, but the studies analysed might be method-
ologically ﬂ awed—eg, they might be underpowered.10 A 
screening study can be designed only if the diagnostic 
eﬀ ectiveness of the screening test has been well 
characterised. The National Institute for Health and Care 
Excellence (NICE) in the UK did a thorough systematic 
review of the evidence about the diagnostic eﬀ ectiveness 
of universal screening for SGA using ultrasonography 
for their 2008 Antenatal Care guideline.3 They concluded 
that, “the methods by which [SGA] can be identiﬁ ed 
antenatally are poorly developed or not tested by rigorous 
methodology”. Furthermore, SGA is frequently used as a 
proxy for fetal growth restriction (FGR). However, in 
reality many SGA infants are physiologically small. Very 
little information is available about the ability of universal 
ultrasonography to identify those SGA fetuses that are at 
increased risk of morbidity (panel).
The aims of this study were to compare the diagnostic 
eﬀ ectiveness of universal ultrasound as a screening test 
for SGA compared with selective ultrasound and to 
establish which, if any, of a series of previously described 
ultrasonic markers of FGR identiﬁ ed those SGA fetuses 
at an increased risk of an adverse outcome.
Methods
Study design and participants
In this prospective cohort Pregnancy Outcome Prediction 
(POP) study, nulliparous women attending for their 
dating ultrasound scan at the Rosie Hospital (Cambridge, 
UK) between Jan 14, 2008, and July 31, 2012, with a viable 
pregnancy were eligible to participate. The protocol has 
been published elsewhere.11 The only clinical exclusion 
criterion was multiple pregnancy. Women were selected 
for clinically indicated ultrasound scans in the third 
trimester as per routine clinical care, and the results of 
these scans were reported (selective ultrasonography). 
All women in the cohort also had research ultrasound 
scans in which both the women and the clinicians caring 
for them were masked to the results (universal 
ultrasonography). After delivery, the results of the 
research scans were unmasked and their associations 
with birthweight less than the 10th percentile and 
neonatal morbidity were assessed. This study was 
designed to generate level 1 evidence of diagnostic 
eﬀ ectiveness, as deﬁ ned by the latest NICE Guideline at 
Panel: Research in context
Systematic review
Previously reported large-scale systematic reviews have addressed 
the ability of universal ultrasonography to result in improved 
clinical outcome. Reported Cochrane reviews have examined both 
conventional ultrasound and use of Doppler ﬂ ow velocimetry of 
the uteroplacental circulation. Neither of these methods has been 
shown to improve outcome. The National Institute for Health and 
Care Excellence (NICE) did a highly detailed review of the methods 
of screening women at low risk for fetal wellbeing for the 2008 
Guideline on Antenatal Care. This guideline included both results 
of the Cochrane reviews of clinical eﬀ ectiveness of universal 
ultrasound and results of the new meta-analyses of diagnostic 
eﬀ ectiveness of screening for small-for-gestational-age (SGA) 
infants. The guideline concluded that high quality evidence on the 
diagnostic eﬀ ectiveness of routine ultrasonography was scarce, 
and recommended several aspects of screening for SGA infants as 
research priorities. It might seem paradoxical that universal ultra-
sonography has not been shown to be beneﬁ cial in randomised 
controlled trials, but NICE recommended further research into its 
diagnostic eﬀ ectiveness. However, this absence of beneﬁ t might 
be attributed to the impossibility of designing an interventional 
study of screening without knowledge of the diagnostic 
eﬀ ectiveness of the screening test in the given population. 
Moreover, many observational studies reported that SGA infants 
are at increased risk of complications, methods used to screen for 
SGA have low sensitivity and speciﬁ city, and undiagnosed SGA is 
a common ﬁ nding in perinatal deaths.
Interpretation
Our study shows that universal use of ultrasound roughly 
tripled the detection of SGA infants. Moreover, by use of a 
combination of assessment of the estimated fetal weight of a 
baby with a previously reported measurement of fetal growth 
restriction (abdominal circumference growth velocity), the 
population of small fetuses could be divided into about 
30% that were growth restricted and at increased risk of 
neonatal morbidity, and about 70% that did not have growth 
restriction and were at the same risk of neonatal morbidity as 
those babies not identiﬁ ed as small by universal ultrasound. 
The statistical associations (for both main eﬀ ects and 
interactions) reported were suﬃ  ciently strong that these 
ﬁ ndings were unlikely to be chance or data driven. These 
results suggest that the screening of unselected nulliparous 
women and identiﬁ cation of growth-restricted fetuses at 
increased risk of an adverse outcome is possible. Additionally, 
the same combination of ﬁ ndings associated with the risk of 
neonatal morbidity could plausibly be predictive of other 
adverse outcomes associated with fetal growth restriction, 
such as antepartum stillbirth. As a result, a programme to 
screen with universal ultrasonography and intervention using 
a care bundle based on the latest Royal College of 
Obstetricians and Gynaecologists guideline might reduce the 
number of adverse perinatal outcomes caused by fetal 
growth restriction. 
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the time.12 Reporting of this study conforms to the 
STROBE (The Strengthening the Reporting of 
Observational Studies in Epidemiology) statement.
Ethical approval for the study was obtained from the 
Cambridgeshire 2 Research Ethics Committee (reference 
07/H0308/163) and approval to study data routinely 
gathered from non-participants was obtained from the 
South Central (Berkshire) Research Ethics Committee 
(reference 12/SC/0344). Participants provided written 
informed consent.
Procedures
Women who agreed to participate were given follow-up 
appointments at about 20, 28, and 36 weeks’ gestation in 
the National Institute for Health Research Cambridge 
Clinical Research Facility (Cambridge, UK). All research 
scans after the dating scan were done with a Voluson 
i system (GE Healthcare, Fairﬁ eld CT, USA) by one of a 
team of six sonographers, all of whom received standard 
training. All ultrasound examinations followed the same 
protocols as those used in the clinical service.13,14 At the 
20 week research appointment, participants were given a 
novel questionnaire we created to obtain details about 
their medical history and demographic characteristics.11 
The 20 week scan had both routine (review of fetal 
anatomy and biometric measurements) and research 
(uterine and umbilical artery Doppler ﬂ ow velocimetry) 
elements. Women were informed about routine elements 
(any concerns about the fetal anatomy and of the fetal 
measurements at the 20 week scan), but women and 
clinicians were masked to the research elements (results 
of the uterine and umbilical Dopplers). At the 28 and 
36 week research appointments, umbilical and uterine 
artery Doppler ﬂ ow velocimetry were repeated, and 
ultrasonographic measurement of fetal biparietal 
diameter, head circumference, abdominal circumference, 
and femur length were also done using standard 
techniques. An estimated fetal weight (EFW) percentile 
was calculated by use of the Hadlock equations and 
reference standard.15,16 Uteroplacental Dopplers, bio-
metry, and EFW results from the research ultrasound 
scans at 28 and 36 weeks were not reported to the 
participant or the clinician. However, both were informed 
about incidental ﬁ ndings, speciﬁ cally previously un-
diagnosed placenta praevia, severe oligohydramnios 
(amniotic ﬂ uid index <5), a previously undiagnosed fetal 
abnormality, or non-cephalic presentation at the time of 
the 36 week scan.
Gestational age was deﬁ ned on the basis of 
ultrasonographic estimation at the time of the ﬁ rst scan, 
as recommended.3 Distributions of all measurements in 
the research scans were similar to previously reported 
reference cohorts (appendix). Summary statistics 
for reproducibility and reliability of research scans 
(assessed by two sonographers, scanning the same 
woman twice at the same appointment, each masked 
to the results of the other’s scan) are tabulated for 
45 women at 20 weeks’ gestation and 44 women at 
36 weeks’ gestation (appendix). Coeﬃ  cients of variation 
were less than 5% for fetal biometry and EFW, and 
between 5% and 10% for uteroplacental Doppler at 
both timepoints.
Women were selected for additional, clinically indicated 
scans in the third trimester of pregnancy as per routine 
clinical care, using local and national guidelines (eg, the 
NICE Guidelines on low risk women,3 women with 
diabetes,17 and women with hypertensive disorders18). 
Women were also screened with serial measurement of 
the symphyseal-fundal height. All women carried their 
maternity notes, which included a chart of the normal 
range of measurements for fetuses in relation to 
gestational age. Referral for an ultrasound scan was 
made by the midwife or doctor providing clinical care. 
Results of all clinically indicated scans were reported and 
paper copies were ﬁ led in both the participant’s hand-held 
notes and hospital case records.
Screening status in relation to EFW was classiﬁ ed on 
the basis of the last scan before birth (which could be the 
For more on the STROBE 
statement see http://www.
strobe-statement.org
See Online for appendix
Figure 1: Study proﬁ le
8028 women eligible
4512 enrolled 
3516 (44%) not recruited
4512 (58%) at 12 week scan
4444 in study
 4418 (98%) at 20 week scan 
 26 missing or delivered
68 lost to follow-up
 45 withdrew consent 
 23 delivered elsewhere
4399  in study
 4305 (95%) at 28 week scan
 94 missing or delivered
45 lost to follow-up
 15 withdrew consent
 30 delivered elsewhere
4327 in study
 4011 (89%) at 36 week scan
 316 missing or delivered
72 lost to follow-up
 5 withdrew consent 
 67 delivered elsewhere
4200 women delivered (157
 <36 week scan), 4043 >36 
 week scan appointment) at 
 Rosie Hospital
3977 (95%) attended all third 
 trimester research scans 
 booked before labour and 
 delivered a liveborn infant 
 ≥26 weeks’ gestational age
127 lost to follow-up 
 127 delivered elsewhere 
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28 week scan or the 36 week scan for universal 
ultrasonography, depending on the gestational age at 
delivery). Screen positive was deﬁ ned as an EFW less 
than the 10th percentile, using an externally derived 
reference range15,16 (for both selective and universal 
ultrasonography). Screen negative was deﬁ ned as an 
EFW of the 10th percentile or more (both selective and 
universal ultrasonography), or if no clinically indicated 
scan had been done at gestational age of 26 weeks or later 
(only selective ultrasonography).
Outcomes
Inclusion criteria for analysis were that women attended 
research scans booked before delivery and had a live 
birth at the Rosie Hospital. We excluded women who 
delivered before their 28 week scan appointment from 
the analysis. The results of clinically indicated scans and 
the outcome of the pregnancy were ascertained by 
individual review of all paper-case records by research 
midwives, and by linkage of the research data to the 
hospitals’ electronic databases of ultrasonography 
(Astraia; Munich, Germany), delivery (Protos; iSoft, 
Banbury, UK), biochemical tests (Meditech; Westwood, 
MA, USA), and neonatal intensive care (Badgernet, 
Clevermed, Edinburgh, UK). The gold standard for SGA 
was birthweight of less than the 10th percentile for sex 
and gestational age, calculated from a UK reference.19 We 
also studied severe SGA (birthweight <3rd percentile) as 
a secondary outcome.
We deﬁ ned neonatal morbidity as one or more of the 
following criteria: a 5 min Apgar score of less than 7, 
delivery with metabolic acidosis (deﬁ ned as a cord blood 
pH <7·1 and base deﬁ cit >10 mmol/L), or admission to 
the neonatal unit at term (deﬁ ned as admission <48 h after 
birth at ≥37 weeks’ gestational age and discharge 
≥48 h after admission). We deﬁ ned severe adverse 
perinatal outcome as stillbirth or term livebirth associated 
with neonatal death, hypoxic ischaemic encephalopathy, 
use of inotropes, need for mechanical ventilation, or 
severe metabolic acidosis (deﬁ ned as a cord blood pH <7·0 
and base deﬁ cit >12 mmol/L: the criteria by which 
international guidelines deﬁ ne fetal metabolic acidosis, 
which can be regarded as cause for cerebral palsy during 
childhood20). This group included seven stillbirths, which 
had been excluded from the main study cohort.
We calculated customised percentiles of EFW on the 
basis of reported methods,21 but used coeﬃ  cients from 
the latest model of Gestation-Related Optimal Weight 
(GROW; version 6.7.3_13 [UK]). We compared associ-
ations between population-based EFW and customised 
EFW of less than the 10th percentile and neonatal 
morbidity. We analysed other indicators of growth 
restriction through comparison of the association 
between an EFW of less than the 10th percentile and 
neonatal morbidity, in the presence or absence of the 
given factor. We quantiﬁ ed Doppler ﬂ ow velocimetry with 
the pulsatility index,14 and uterine artery pulsatility index 
as the mean pulsatility index of the left and right uterine 
arteries, classiﬁ ed by the measurement at the 20 week 
scan.14 We classiﬁ ed umbilical artery pulsatility index, 
No clinically 
indicated scan 
≥26 weeks 
(n=2311)
One or more 
clinically 
indicated scan 
≥26 weeks 
(n=1666)
p value Overall 
baseline 
characteristics 
(N=3977)
Maternal characteristics
Age (years) <0·0001
<20 66 (3%) 73 (4%) ¨ 139 (4%)
20–24·9 311 (13%) 209 (13%) ¨ 520 (13%)
25–29·9 757 (33%) 468 (28%) ¨ 1225 (31%)
30–34·9 887 (38%) 598 (36%) ¨ 1485 (37%)
35–39·9 274 (12%) 260 (16%) ¨ 534 (13%)
≥40 16 (1%) 58 (3%) ¨ 74 (2%)
Age stopped FTE (years) 0·01
<19 728 (32%) 593 (36%) ¨ 1321 (33%)
19–22 828 (36%) 555 (33%) ¨ 1383 (35%)
≥23 697 (30%) 463 (28%) ¨ 1160 (29%)
Missing 58 (3%) 55 (3%) NA 113 (3%)
Deprivation quartile 0·18
1 (lowest) 574 (25%) 400 (24%) ¨ 974 (24%)
2 550 (24%) 393 (24%) ¨ 943 (24%)
3 561 (24%) 399 (24%) ¨ 960 (24%)
4 (highest) 523 (23%) 416 (25%) ¨ 939 (24%)
Missing 103 (4%) 58 (3%) NA 161 (4%)
Postcode area 0·17
CB1–5 709 (31%) 514 (31%) ¨ 1223 (31%)
CB21–25 528 (23%) 374 (22%) ¨ 902 (23%)
CB6–11 549 (24%) 446 (27%) ¨ 995 (25%)
Outside Cambridgeshire 459 (20%) 302 (18%) ¨ 761 (19%)
Missing 66 (3%) 30 (2%) NA 96 (2%)
Ethnic origin 
White 2151 (93%) 1545 (93%) 0·65 3696 (93%)
Missing 40 (2%) 29 (2%) NA 69 (2%)
Married 1576 (68%) 1151 (69%) 0·55 2727 (69%)
Smoker 106 (5%) 79 (5%) 0·82 185 (5%)
Alcohol consumption
Any 117 (5%) 66 (4%) 0·10 183 (5%)
Missing 1 (<1%) 0 (0%) NA 1 (<1%)
BMI (kg/m2) <0·0001
<25 1416 (61%) 909 (55%) ¨ 2325 (58%)
25–29·9 667 (29%) 450 (27%) ¨ 1117 (28%)
30–34·9 209 (9%) 168 (10%) ¨ 377 (9%)
35–39·9 18 (1%) 92 (6%) ¨ 110 (3%)
≥40 1 (<1%) 46 (3%) ¨ 47 (1%)
Missing 0 (0%) 1 (<1%) NA 1 (<1%)
≥1 previous miscarriage 207 (9%) 199 (12%) 0·002 406 (10%)
Diabetes <0·0001
Type 1 or type 2 0 (0%) 14 (1%) ¨ 14 (<1%)
Gestational 2 (<1%) 160 (10%) ¨ 162 (4%)
Missing 3 (<1%) 2 (<1%) NA 5 (<1%)
(Table 1 continues on next page)
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head circumference-to-abdominal circumference ratio, 
and abdominal circumference-to-femur length ratio by 
the last measurement taken before birth. We quantiﬁ ed 
all measurements as gestational age adjusted Z scores, to 
account for variation in the exact timing of ultrasound 
scans (appendix). We quantiﬁ ed growth velocity as the 
diﬀ erence in abdominal circumference Z score, 
comparing the last scan before birth and the scan at 
20 weeks. For all ﬁ ve of these indices, we generated 
deciles by use of the distribution in the study cohort. 
We deﬁ ned as abnormal the highest deciles of head 
circumference-to-abdominal circumference ratio, uterine 
Doppler, and umbilical Doppler in addition to the lowest 
deciles of abdominal circumference-to-femur length ratio 
and abdominal circumference growth velocity. We did not 
investigate other growth indices to reduce the possibility 
of chance ﬁ ndings due to repeated hypothesis tests. 
Our study did not include Doppler assessment of blood 
ﬂ ow in fetal vessels (eg, ductus venosus or middle 
cerebral artery).
Statistical analysis
We used an open-ended recruitment approach, to provide 
increased power for the less common adverse outcomes 
with greater cohort size. In our protocol paper11 we 
identiﬁ ed a sample size of 4000 women as providing 
reasonably precise estimates of sensitivity for outcomes 
aﬀ ecting 3% of the population.
We compared continuous variables with a two-sample 
Wilcoxon rank-sum test and categorical variables with the 
Pearson χ² test, with a trend test if appropriate, or Fisher’s 
exact test if numbers were small. We compared sensitivity, 
speciﬁ city, false positive rate, and false negative rate using 
McNemar’s test; positive and negative predictive values 
using weighted generalised score tests;22 and likelihood 
ratios using regression model-based tests.23 We did a 
series of post-hoc sensitivity analyses in which we 
included women who had defaulted from their research 
scans (at 28 or 36 weeks), and excluded women who had 
their research scan results shown to them for any reason, 
and in which we combined the results of universal and 
selective ultrasonography. We tested interactions between 
EFW and ultrasonic markers of FGR in their associations 
with neonatal morbidity by the Mantel-Haenszel test. We 
deﬁ ned signiﬁ cance as p<0·05 (two-sided). We did not 
make formal adjustments for multiple comparisons and 
did not adjust for maternal baseline characteristics.
Analyses were done with Stata software (version 13.1) 
and R software (version 3.0.2).
Role of the funding source
The funders of this study had no role in study design, 
data analysis, data interpretation, or writing of the 
report. The corresponding author and a coauthor (US) 
had full access to data used in the study. The 
corresponding author had ﬁ nal responsibility for the 
decision to submit the paper for publication.
Results
Between Jan 14, 2008, and July 31, 2012, we identiﬁ ed 
8028 eligible women of whom 4512 (56%) provided written 
informed consent and were enrolled, whereas 3516 (44%) 
women declined to participate or were not approached by a 
study recruiter. Although recruited and non-recruited 
women were broadly comparable with each other, those 
recruited were slightly older in age, more often of white 
ethnic origin, less likely to smoke, more likely to have a 
caesarean delivery, and had infants of slightly heavier 
birthweights (appendix). 3977 (88%) of 4512 women 
recruited were included in the data analysis (ﬁ gure 1).
1666 (42%) women had a clinically indicated scan 
including biometry at gestation of 26 weeks or more, and 
2311 (58%) women did not (table 1). Women having 
clinically indicated scans were more likely to be at extremes 
of maternal age (<20 years and ≥40 years) than those 
women not having clinically indicated scans and were 
more likely to have discontinued education early in life 
(<19 years), a body-mass index greater than 30 kg/m², had 
previous miscarriages, and to have pre-existing diabetes or 
to develop gestational diabetes. Average birthweight of the 
For the 2013 Gestation 
Network Gestation-Related 
Optimal Weight Customised 
Weight Centile Calculator see 
http://www.gestation.net
No clinically 
indicated scan 
≥26 weeks 
(n=2311)
One or more 
clinically 
indicated scan 
≥26 weeks 
(n=1666)
p value Overall 
baseline 
characteristics 
(N=3977)
(Continued from previous page)
Birth outcomes
Birthweight (g) 3480
(3175–3770)
3345 
(3010–3685)
<0·0001 3420 
(3105–3740)
SGA (<10th) 178 (8%) 174 (10%) 0·003 352 (9%)
Severe SGA (<3rd) 34 (1%) 53 (3%) 0·0003 87 (2%)
Gestational age (weeks) <0·0001
Preterm (26–32) 15 (1%) 15 (1%) ¨ 30 (1%)
Preterm (33–36) 53 (2%) 80 (5%) ¨ 133 (3%)
Term (≥37) 2243 (97%) 1571 (94%) ¨ 3814 (96%)
Induction of labour
Yes 629 (27%) 629 (38%) <0·0001 1258 (32%)
Missing 4 (<1%) 2 (<1%) NA 6 (<1%)
Mode of delivery <0·0001
Spontaneous vaginal 1218 (53%) 706 (42%) ¨ 1924 (48%)
Assisted vaginal 596 (26%) 353 (21%) ¨ 949 (24%)
Intrapartum caesarean 415 (18%) 283 (17%) ¨ 698 (18%)
Prelabour caesarean 74 (3%) 317 (19%) ¨ 391 (10%)
Missing 8 (<1%) 7 (<1%) NA 15 (<1%)
Data are n (%) or median (IQR). p values are for diﬀ erence between groups calculated using the two-sample Wilcoxon 
rank-sum (Mann-Whitney) test for continuous variables and the Pearson χ² test for categorical variables, with trend 
tests if appropriate. The “missing” category was not included in statistical tests. For characteristics that have no 
“missing” category, data were 100% complete. Maternal age was deﬁ ned as age at recruitment to study. All other 
maternal characteristics were deﬁ ned by self-report at the 20 weeks questionnaire, from examination of the clinical 
case record, or linkage to the hospital’s electronic databases. Socioeconomic status was quantiﬁ ed by use of the Index 
of Multiple Deprivation24 2007, which is based on census data from the area of the mother’s postcode. FTE=full-time 
education. CB1–5=central Cambridge city. CB21–25=peripheral Cambridge city. CB6–11=Cambridgeshire, outside city. 
NA=not applicable. BMI=body-mass index. SGA=small for gestational age. 
Table 1: Characteristics of the study cohort 
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infants born to this group of women was lower, and they 
had a greater proportion of SGA infants, preterm births, 
induced labours, and caesarean deliveries than women 
who did not have clinically indicated scans.
352 (9%) infants had a birthweight of less than the 
10th percentile. The last clinically indicated scan before 
birth recorded an EFW of less than the 10th percentile 
in 138 (8%) of 1666 women, with 69 of these women 
going on to have babies with birthweight less than the 
10th percentile, yielding a sensitivity of 20% (69 of 352) 
infants. The last research ultrasound scan before birth 
recorded an EFW of less than the 10th percentile in 
562 women; 199 of these women had babies with a 
birthweight less than the 10th percentile, yielding a 
sensitivity of 57% (199 of 352). Tables 2 and 3 compare 
universal and selective ultrasonography as a two-by-two 
table and as showing screening summary statistics, 
respectively. All analyses were repeated with the outcome 
of severe SGA. Areas under the receiver operating 
characteristic curve for universal ultrasonography were 
0·87 (95% CI 0·85–0·88) for SGA and 0·91 (0·89–0·94) 
for severe SGA (appendix). Diagnostic eﬀ ectiveness of 
the 28 and 36 week research scans are presented 
separately, and also described for each in relation to the 
interval between the scan and the delivery date 
(appendix). Sensitivity analyses generated very similar 
results to the main analysis (appendix).
The relative risk of any neonatal morbidity associated 
with EFW of less than the 10th percentile was 
1·6 (95% CI 1·2–2·1, p=0·001; table 4). Deﬁ nition of EFW 
with customised percentiles did not result in a stronger 
association. The association between an EFW lower than 
the 10th percentile and the risk of neonatal morbidity was 
then assessed in relation to ﬁ ve previously reported 
indices of fetal growth restriction (ﬁ gure 2). Only the 
measurement of abdominal circumference growth 
velocity was associated with strong evidence for an 
interaction (p=0·005). Screen positive fetuses with normal 
growth velocity were not at increased risk of neonatal 
morbidity, whereas an EFW of less than the 10th percentile 
was associated with an increase of 3·9 times (95% CI 
1·9–8·1) of neonatal morbidity in infants in the lowest 
decile of abdominal circumference growth velocity. 
172 (4·3%) fetuses had the combination of an ultrasonic 
diagnosis of SGA plus the lowest decile of abdominal 
circumference growth velocity from universal ultra-
sonography. This combination was associated with a 
relative risk of any morbidity of 2·5 (95% CI 1·7–3·6) and 
relative risk of delivering an SGA infant with neonatal 
morbidity of 17·6 (9·2–34·0; table 4). Similar associations 
were reported when the analysis was repeated for severe 
adverse perinatal outcome, with a relative risk of 
2·9 (95% CI 1·0–8·3, p=0·058) for any severe adverse 
outcome and 39·8 (95% CI 3·6–436·6, p=0·007) for 
severe adverse outcome in an SGA infant. We repeated all 
analyses of abdominal circumference growth velocity 
using abdominal circumference growth charts generated 
by the Fetal Growth Longitudinal Study component of 
the INTERGROWTH-21st Project,25 an international 
consortium that established fetal growth standards using 
methods recommended by WHO. All associations 
were very similar when the standards from the 
INTERGROWTH-21st Project were used (appendix). The 
combination of ultrasonic diagnosis of SGA infants plus 
SGA Severe SGA
Yes No Total Yes No Total
Selective ultrasonography
EFW <10th 69 69 138 28 110 138
EFW ≥10th or no scan 283 3556 3839 59 3780 3839
Total 352 3625 3977 87 3890 3977
Universal ultrasonography
EFW <10th 199 363 562 67 495 562
EFW ≥10th 153 3262 3415 20 3395 3415
Total 352 3625 3977 87 3890 3977
Selective ultrasonography shows the results of clinically indicated scans. Of the 
1666 women selected for ultrasonography at 26 weeks or later, 1388 (83%) had 
one or two scans, 245 (15%) had three or four scans, and 33 (2%) had ﬁ ve or more 
scans. If a woman did not have a clinically indicated scan after the routine 
anomaly scan she was deﬁ ned as screen negative by selective ultrasonography. 
Universal ultrasonography shows the results of the last research scan done before 
birth (either the 28 week scan or the 36 week scan, depending on the gestational 
age at delivery). Median time interval (IQR) between the last selective scan and 
birth was 3·1 weeks (1·6–5·6 weeks), and between the last universal scan and 
birth was 4·1 weeks (3·1–5·0 weeks). SGA=small for gestational age 
(birthweight <10th percentile; severe SGA birthweight <3rd percentile). 
EFW=estimated fetal weight (from the last scan before birth).
Table 2: Screening eﬀ ectiveness for selective and universal 
ultrasonographic screening for infants who are small and severely small 
for gestational age 
SGA Severe SGA
Selective Universal Selective Universal
Sensitivity (%) 20% (15–24) 57% (51–62) 32% (22–42) 77% (68–86)
Speciﬁ city (%) 98% (98–99) 90% (89–91) 97% (97–98) 87% (86–88)
Positive predictive value 
(%)
50% (42–58) 35% (31–39) 20% (14–27) 12% (9–15)
Negative predictive value 
(%)
93% (92–93) 96% (95–96) 98% (98–99) 99% (99–100)
False positive rate* (%) 2% (1–2) 10% (9–11) 3% (2–3) 13% (12–14)
False negative rate† (%) 80% (76–85) 43% (38–49) 68% (58–78) 23% (14–32)
Positive likelihood ratio 10·3 (7·5–14·1) 5·6 (4·9–6·5)‡ 11·4 (8·0–16·3) 6·1 (5·3–7·0)
Negative likelihood ratio 0·8 (0·8–0·9) 0·5 (0·4–0·5)‡ 0·7 (0·6–0·8) 0·3 (0·2–0·4)
Relative sensitivity 1·0 (reference) 2·9 (2·4–3·5) 1·0 (reference) 2·4 (1·8–3·2)
95% CIs are given in brackets. All values were calculated with estimated fetal weight <10th percentile as screen 
positive. Statistical comparison by McNemar, weighted generalised score tests, or regression model-based tests as 
appropriate. All comparisons of selective vs universal had p<0·0001 for both outcomes, except for SGA positive 
likelihood ratio (p=0·0001), severe SGA positive predictive value (p=0·0002), and positive likelihood ratio (p=0·0003). 
SGA=small for gestational age (birthweight <10th percentile; severe SGA birthweight <3rd percentile). *Deﬁ ned as 
proportion of screen positives among non-SGA infants. †Deﬁ ned as proportion of screen negatives among SGA 
infants. ‡Sample calculation: positive likelihood ratio=(199 ÷ 363)/(352 ÷ 3625)=5·6; negative likelihood 
ratio=(153 ÷ 3262)/(352 ÷ 3625)=0·5. 
Table 3: Diagnostic eﬀ ectiveness of selective versus universal ultrasonographic screening for infants who 
are small and severely small for gestational age 
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lowest decile of abdominal circumference growth velocity 
(deﬁ ned by the INTERGROWTH-21st Project standards) 
was associated with a relative risk of 2·5 (95% CI 1·7–3·5, 
p<0·0001) for any morbidity, 17·6 (9·4–33·0, p<0·0001) 
for delivering an SGA infant with neonatal morbidity, 
2·5 (0·9–7·0, p=0·09) for severe adverse perinatal 
outcome, and 33·4 (3·0–366·6, p=0·009) for delivering an 
SGA infant with severe adverse perinatal outcome). 
Finally, no indicator of FGR was associated with adverse 
outcome if the EFW was above the 10th percentile 
(appendix).
Discussion
Fetal growth restriction is associated with many adverse 
outcomes including stillbirth,26 neonatal death,27 hypoxic 
ischaemic encephalopathy,28 cerebral palsy,29 special 
educational needs,30 and many diseases in adult life.31 The 
present standard of care in the USA,2 UK,3 and many other 
countries is that women are selected for third trimester 
ultrasonographic fetal biometry on the basis of speciﬁ c 
indications. From our study of a population of nulliparous 
women of mixed risk with a singleton pregnancy, we 
showed that selective use of ultrasonography identiﬁ ed 
one in ﬁ ve infants with a birthweight of less than the 
10th percentile, which is similar to reports from other 
centres.4–6 Additionally, a policy of screening with universal 
ultrasonographic estimation of fetal weight at 28 and 
36 weeks’ gestational age roughly tripled the sensitivity of 
detection of SGA infants. However, the speciﬁ city was 
higher for selective ultrasonography (98%) than universal 
ultrasonography (90%). After the absolute numbers of true 
and false positives were calculated, our ﬁ ndings showed 
that for every additional SGA infant correctly identiﬁ ed by 
universal ultrasonography, about two additional results 
were false positives.
On the basis of these results, implementation of 
universal ultrasonographic screening would likely 
increase the detection of SGA infants. However, it would 
also substantially increase the number of false positive 
results. The net eﬀ ect on clinical outcomes would depend 
on the balance between any beneﬁ ts that arise from 
identiﬁ cation of true positives versus any harm caused by 
false positives. However, even correct identiﬁ cation of 
SGA infants has the potential to cause unnecessary 
intervention. The population of SGA infants is well 
recognised to consist of both those that are healthy but 
small in size and those with restricted growth. We 
Any neonatal 
morbidity (n=275)
Metabolic 
acidosis (n=42)
5 min Apgar <7 
(n=36)
Neonatal unit 
admission 
(n=229)
SGA plus any neonatal 
morbidity (n=49)
Severe adverse 
perinatal outcome 
(n=33)
SGA plus severe 
adverse perinatal 
outcome (n=5)
RR 
(95% CI)
p value RR 
(95% CI)
p value RR 
(95% CI)
p value RR 
(95% CI)
p value RR 
(95% CI)
p value RR 
(95% CI)
p value RR
(95% CI)
p value
EFW <10th (population) 1·6
(1·2–2·1)
0·001 1·4
(0·7–3·1)
0·37 2·3
(1.1–4·8)
0·03 1·6
(1·2–2·1)
0·006 10·5
(5·9–18·6)
<0·0001 1·4
(0·6–3·3)
0·45 24·3
(2·7–217·1)
0·002
EFW <10th 
(customised*)
1·7
(1·3–2·3)
0·001 1·5
(0·6–3·4)
0·44 1·7
(0·7–4.2)
0·26 1·6
(1·2–2·3)
0·01 9·8
(5·7–17·1)
<0·0001 1·9
(0·8–4·7)
0·14 34·8
(3·9–310·4)
0·0005
EFW <10th plus normal 
ACGV
1·3
(0·9–1·8)
0·23 0·3
(0·0–1·9)
0·25 1·4
(0.5–3·9)
0·54 1·4
(0·9–2·0)
0·13 7·3
(3·7–14·4)
<0·0001 0·7
(0·2–2·7)
0·76 17·6
(1·6–193·5)
0·03
EFW <10th plus lowest 
decile ACGV
2·5
(1·7–3·6)
<0·0001 4·1
(1·8–9·1)
0·003 4·6
(1·9–11·0)
0·004 2·1
(1·3–3·2)
0·003 17·6
(9·2–34·0)
<0·0001 2·9
(1·0–8·3)
0·06 39·8
(3·6–436·6)
0·007
All estimated fetal weights (EFWs) are based on population-based percentiles, unless stated otherwise. All relative risks (RRs) are referent to infants with an EFW of ≥10th percentile by population-based 
standards, except for the RRs for customised EFW <10th percentile, which are referent to infants with an EFW of the ≥10th percentile by customised standards. Appendix has n/N for every cell. Small for 
gestational age (SGA) is defined as birthweight of <10th percentile by population standards. Abdominal circumference growth velocity (ACGV) is based on the change in the gestational age adjusted Z score, 
comparing the result at the 20 week scan with the last scan before birth. Neonatal morbidity is a composite outcome—ie, one or more of these three outcomes: metabolic acidosis (defined as pH <7·1 and base 
deficit >10 mmol/L), 5 min Apgar score less than 7, and neonatal unit admission (defined as admission to the neonatal intensive care unit, the high dependency unit, or the special care baby unit). Severe adverse 
perinatal outcome is a composite outcome—ie, one or more of the following outcomes specified: stillbirth (not due to congenital anomaly), neonatal death at term (not due to congenital anomaly), hypoxic 
ischaemic encephalopathy at term, use of inotropes at term, mechanical ventilation at term, severe metabolic acidosis at term (defined as pH <7·0 and base deficit >12 mmol/L). p values (all two sided) are from 
Fisher’s exact test. *Customised percentiles of EFW were calculated with the Gestation-Related Optimal Weight Customised Weight Centile Calculator (version 6.7 [UK]).
Table 4: Association between perinatal outcomes of estimated fetal weight less than the 10th percentile and abdominal circumference growth velocity
Figure 2: Stratiﬁ ed analyses of the risk of the neonatal composite adverse outcome associated with diagnosis 
of small-for-gestational-age infants
Diagnosis of infants by universal ultrasonography in relation to indicators of fetal growth restriction. The 
ﬁ ve previously described indices of fetal growth restriction were classiﬁ ed as the extreme decile associated with 
fetal growth restriction (highest or lowest, as appropriate) compared with the other nine deciles in the cohort. 
Points are relative risks of neonatal morbidity associated with an ultrasonic diagnosis of a small-for-gestational-
age infant at the last scan before birth. p values are a Mantel-Haenszel test calculation of interaction (ie, testing the 
hypothesis that the association between diagnosis of a small-for-gestation-age infant and neonatal morbidity 
varies in the two strata). Interactions tested using logistic regression showed almost identical p values. 
AC=abdominal circumference. FL=femur length. HC=head circumference. 
Umbilical doppler
Uterine doppler
AC growth velocity
AC:FL ratio
HC:AC ratio
Reference
Highest decile
Reference
Highest decile
Reference
Lowest decile
Reference
Lowest decile
Reference
Highest decile
Overall
p=0·04
p=0·27
p=0·005
p=0·66
p=0·09
Relative risk (95% CI)
210·5 4 8 16
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postulated that eﬀ ective markers of growth restriction 
would identify the small fetuses who were at increased 
risk of neonatal morbidity and assessed ﬁ ve previously 
described ultrasonographic markers of FGR (ﬁ gure 2). 
The only measurement that had strong evidence for 
an interaction was the fetal abdominal circumference 
growth velocity. In all other cases, SGA infants were still 
at increased risk of morbidity if the indicator of FGR 
was normal. By contrast, an EFW of less than the 
10th percentile was not associated with neonatal 
morbidity if the infant’s abdominal circumference 
growth velocity was normal, but was associated with 
about a four times increased risk of neonatal morbidity if 
the abdominal circumference growth velocity was in the 
lowest decile. Furthermore, comb ination of an EFW of 
less than the 10th percentile plus an abdominal 
circumference growth velocity in the lowest decile was 
associated with about an 18 times increased risk of 
mothers delivering an SGA infant with neonatal 
morbidity, and about a 40 times increased risk of 
mothers delivering an SGA infant with a severe adverse 
perinatal outcome. We repeated the analyses using the 
2014 international reference standard to quantify 
abdominal circumference growth velocity25 and the 
results were largely identical.
Our results showed that customisation of the EFW 
did not increase the strength of association between 
SGA and neonatal morbidity. The process of 
customisation attempts to relate the estimated size of a 
fetus to its genetic potential, using the maternal 
characteristics. We interpreted the ﬁ ndings of this 
study to suggest that the size of a fetus at the 20 week 
scan might be a better proxy of its genetic growth 
potential than the maternal characteristics. Our ﬁ nding 
that abdominal circumference growth velocity was 
better than either uterine or umbilical Doppler to 
distinguish between SGA infants at low risk and high 
risk is consistent with the view that poor growth could 
be an endpoint of several pathological changes. Hence, 
assessment of growth velocity might be a more 
appropriate marker of adverse outcome as additional 
speciﬁ c tests only provide information about a subset of 
FGR caused by a speciﬁ c pathophysiological pathway.
Our study has strengths and weaknesses. One of the 
strengths is that clinicians were blinded to the results of 
research ultrasonographic assessments of fetal biometry 
and uteroplacental Doppler. The justiﬁ cation for 
concealment of the results of the research biometry and 
uteroplacental Doppler was taken from the NICE 
recommendation that these scans should not be oﬀ ered 
routinely.3 The rationale for concealment of the biometry 
was that if the results had been known, they might have 
biased subsequent assessment of symphyseal-fundal 
height. A limitation of our study is that it was conﬁ ned to 
nulliparous women. The rationale for selection of this 
group was that nulliparous women have higher rates of 
SGA than multiparous women and, by deﬁ nition, no 
information is available about any history of previous SGA 
births in this group, which is one of the strongest 
predictors of SGA in a pregnancy. However, further studies 
are needed to establish whether universal ultrasonography 
is also eﬀ ective in multiparous women. The major single 
cause of non-anomalous perinatal deaths at term is 
antepartum stillbirth, and about 30% of these stillbirths 
are associated with poor fetal growth.32 Although stillbirth 
was included in our composite of severe adverse outcome, 
our study was underpowered to investigate stillbirth 
directly. However, we speculate that the same ultrasonic 
features associated with neonatal morbidity and the 
composite of severe adverse perinatal outcome are likely to 
be associated with the risk of stillbirth.
In conclusion, we showed that universal third 
trimester ultrasound tripled the detection of SGA infants 
and could identify FGR fetuses that were at increased 
risk of neonatal morbidity. The guideline1 from the Royal 
College of Obstetricians and Gynaecologists (RCOG) 
lists a series of evidence-based recommendations for 
the management of suspected FGR—including fetal 
monitoring, timing of induction of labour, and how to 
undertake delivery.1 We believe that a programme of 
screening that includes universal ultrasonography and 
intervention following a care bundle based on the latest 
RCOG guideline1 has the potential to reduce the number 
of adverse perinatal outcomes caused by FGR.
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